Prevalence and predictors for adverse effects of Sinopharm and Sinovac COVID-19 Vaccines.

Abstract

Objective: To see the prevalence and potential predictors for side effects of Sinopharm and Sinovac COVID-19 vaccines among students of medical, and BS human nutrition and dietetics courses. Study Design: Cross-sectional Proforma-derived. Setting: Sialkot Medical College, Sialkot, Pakistan. Period: July and August, 2021. Material & Methods: Fifty students (MBBS = 30; Dietetics course = 20) with at least one dose of Sinopharm or Sinovac COVID-19 vaccine were recruited, purposively. The subjects were asked to report in an indigenously designed proforma on adverse effects using recall methodology for open time. Results: Forty nine subjects gave complete responses in the proforma. The rate of adverse effects increased from 75% (n = 3) against Sinopharm to 100% (n = 9) against Sinovac vaccine among 13 students of Dietetics who had only 1st dose. For rest of the 36 participants, the rate was found, as: 76.5% (n = 13) against each of the 1st and 2nd dose of Sinopharm; 78.9% (n = 15) against 1st and 68.4 (n = 13) against 2nd doses of Sinovac vaccine. The frequency of different adverse effects per individual ranged 1-3 (Sinopharm) or 1-4 (Sinovac). Whereas, lower rate of injection site pain was recorded on 1st dose of Sinopharm than Sinovac (52.9 vs 57.9%, respectively). None of the variables was noted as potential predictor for the side effects (p >.05). Conclusion: Sinopharm, and Sinovac COVID-19 vaccines exhibit almost similar prevalence of self-manageable side effects. Moreover, there is no predictor for the effects.